Evogene Statistics
Total Valuation
Evogene has a market cap or net worth of $9.24 million. The enterprise value is $11.97 million.
Important Dates
The last earnings date was Thursday, November 20, 2025, before market open.
| Earnings Date | Nov 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Evogene has 8.72 million shares outstanding. The number of shares has increased by 40.93% in one year.
| Current Share Class | 8.72M |
| Shares Outstanding | 8.72M |
| Shares Change (YoY) | +40.93% |
| Shares Change (QoQ) | +20.63% |
| Owned by Insiders (%) | 0.99% |
| Owned by Institutions (%) | 2.13% |
| Float | 8.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.15 |
| Forward PS | 1.11 |
| PB Ratio | 0.54 |
| P/TBV Ratio | 8.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.11, with a Debt / Equity ratio of 0.15.
| Current Ratio | 5.11 |
| Quick Ratio | 4.41 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -70.63% and return on invested capital (ROIC) is -61.96%.
| Return on Equity (ROE) | -70.63% |
| Return on Assets (ROA) | -30.60% |
| Return on Invested Capital (ROIC) | -61.96% |
| Return on Capital Employed (ROCE) | -73.64% |
| Revenue Per Employee | $68,513 |
| Profits Per Employee | -$23,496 |
| Employee Count | 117 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 1.57 |
Taxes
In the past 12 months, Evogene has paid $8,000 in taxes.
| Income Tax | 8,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.97% in the last 52 weeks. The beta is 1.57, so Evogene's price volatility has been higher than the market average.
| Beta (5Y) | 1.57 |
| 52-Week Price Change | -23.97% |
| 50-Day Moving Average | 1.21 |
| 200-Day Moving Average | 1.26 |
| Relative Strength Index (RSI) | 45.63 |
| Average Volume (20 Days) | 48,221 |
Short Selling Information
| Short Interest | 95,469 |
| Short Previous Month | 65,047 |
| Short % of Shares Out | 1.10% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.23 |
Income Statement
In the last 12 months, Evogene had revenue of $8.02 million and -$2.75 million in losses. Loss per share was -$0.37.
| Revenue | 8.02M |
| Gross Profit | 5.21M |
| Operating Income | -16.21M |
| Pretax Income | -10.41M |
| Net Income | -2.75M |
| EBITDA | -14.56M |
| EBIT | -16.21M |
| Loss Per Share | -$0.37 |
Full Income StatementBalance Sheet
The company has $15.96 million in cash and $2.52 million in debt, giving a net cash position of $13.44 million or $1.54 per share.
| Cash & Cash Equivalents | 15.96M |
| Total Debt | 2.52M |
| Net Cash | 13.44M |
| Net Cash Per Share | $1.54 |
| Equity (Book Value) | 17.25M |
| Book Value Per Share | 0.13 |
| Working Capital | 16.76M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.38 million and capital expenditures -$451,000, giving a free cash flow of -$15.83 million.
| Operating Cash Flow | -15.38M |
| Capital Expenditures | -451,000 |
| Free Cash Flow | -15.83M |
| FCF Per Share | -$1.82 |
Full Cash Flow StatementMargins
Gross margin is 65.01%, with operating and profit margins of -202.20% and -34.29%.
| Gross Margin | 65.01% |
| Operating Margin | -202.20% |
| Pretax Margin | -129.83% |
| Profit Margin | -34.29% |
| EBITDA Margin | -181.64% |
| EBIT Margin | -202.20% |
| FCF Margin | n/a |
Dividends & Yields
Evogene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -40.93% |
| Shareholder Yield | -40.93% |
| Earnings Yield | -29.76% |
| FCF Yield | -171.33% |
Analyst Forecast
The average price target for Evogene is $3.50, which is 215.32% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.50 |
| Price Target Difference | 215.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on July 25, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jul 25, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Evogene has an Altman Z-Score of -15.16 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.16 |
| Piotroski F-Score | 2 |